Loading stock data…
TMCI
$1.86+0.05 (+2.76%)
Market ClosedLast close May 1
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Treace Medical Concepts, Inc. in the Healthcare sector is trading at $1.86. The stock is currently near its 52-week low of $1.17, remaining 52.9% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why TMCI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.86
Potential Upside
5%
Whystock Fair Value$1.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Hold
Mean target$4.25+128.5%
Range$2.00 – $7.00
Fundamentals
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$121.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.31%
Volume
Today's trading volume
330,002
Recent News
How The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product Plans
The latest update to Treace Medical Concepts' fair value estimate to US$4.25 from US$3.85 comes at a time when analysts remain split, with price targets spread between roughly US$2 and US$7. This range reflects differing views on how quickly growth and product mix might settle, and it helps explain why ratings currently span Hold, Neutral, and Buy. As you read on, you will see how these shifting targets feed into the broader story and what to watch as the narrative continues to...
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks
The United States market has shown robust performance, climbing 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In this context of market growth, identifying stocks with strong financials can be crucial for investors seeking potential opportunities. Penny stocks, though often seen as a term from earlier market days, still represent a segment where smaller or newer companies might offer both affordability and significant growth potential.
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How The Story Is Shifting For Treace Medical Concepts (TMCI) After Analyst Target Resets
Analysts have shifted their price targets on Treace Medical Concepts into a lower single digit range, with modelled fair value moving from US$4.20 to US$3.85 as part of a refreshed view on the stock. This reset lines up with a split narrative, where bullish voices highlight supportive Q4 data and perceived limited downside, while more cautious analysts point to execution risks and mixed product trends. As you read on, you will see how these differing views are shaping the evolving story...
Treace Medical Concepts, Inc. Q4 2025 Earnings Call Summary
Moby summary of Treace Medical Concepts, Inc.'s Q4 2025 earnings call